2018 4TS TOP TO TOE TRANSCATHETER SOLUTIONS CONFERENCE
Dubai Festival City #Dubai, UAE
Dear Colleagues and Friends,
In association with Emirate Cardiac Society, American College of Cardiology and International Society of Endovascular Specialists in addition to more than 15 other international cardiovascular societies we had great success of the third meeting of 4TS international conference last year.
We are looking forward for the 4TS 2018 conference which will be held in February 15-17 in Dubai..
In this meeting we expect to have more than hundred eminent local / regional and international speakers and hundreds of delegates from the region and internationally.
This is a first class meeting involving multidisciplinary team including cardiologist, radiologist, vascular surgeons, cardiac surgeons, lipidologists, neurologist and neuron surgeons in addition to nurses and technicians. Discussing the team approach to different cardiovascular patients.
There will be many case presentations of cases from the intracranial interventions, to carotids, coronary, valvular structural heart disease aortic and lower extremities interventions in addition to, lectures, debates, live cases and hands on workshops.
On behalf of the Scientific Board and Organizing Committee and myself, we are delighted to invite to have active role in this exciting and informative meeting in this futuristic city of Dubai.
Looking forward to see at 4TS 2018!
Omar K Hallak, MD
Founder and Chairman
4TS - Top To Toe Transcatheter Solutions
A. Sunarya Soerianata
Guillermo Ramón Aguilar Peralta
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
Abstract submission deadline 2017-12-19
All abstracts must be submitted in English using the online submission form on 4TS 2018 website.
NOTE: Abstracts submitted by email, fax or post will NOT be accepted. The Scientific Committee will not accept responsibility for any abstracts that have not been properly submitted according to the instructions.
Corresponding authors must provide the organizers with their full mailing address, office hours phone number, fax number and email address. Author and co-author information must be provided including the first and last names of all authors, their department, institution/ hospital, city, state if applicable and country.
Abstracts must contain original scientific data collected by the author(s). All abstracts will be reviewed by the Scientific Committee. The Scientific Committee reserves the right to determine whether a submission is accepted as an oral, video or a poster presentation and its decision is final. The Scientific Committee reserves the right to edit abstracts for grammar and clarity.
The abstract may be scheduled for presentation on any day from 15th – 17th February 2018
Abstract Format Structure
Abstract Title: The title must be brief, concise, and in CAPITAL LETTERS.
Abstract title limit: 20 words
Authors: Please enter your name and your colleagues’ names as you wish them to appear in the Final Program.
Maximum number of words: The abstract text should have a minimum of 250 words and maximum of 300 words only.
The Scientific Committee reserves the rights to reject any submission
A maximum of 2 tables can be submitted and each table should only have a maximum of 5 columns and 10 rows. All figures/ tables/ graphs included in the abstract must be submitted in JPG/ BMP / GIF format with a maximum width of 9cm, and resolution up to 150 dpi. Only TWO figures/ tables/ graphs are allowed for each abstract.
A maximum of 2 figures can be submitted and should be in jpg/ bmp / gif formats with a maximum of 350 pixels and 200 KB/
Please note that these figures/ tables/ graphs may be resized to fit the final printed material.
Do not include references in the abstract.
Do not include keywords in the abstract.
Abbreviations should be spelled out, in parenthesis, in its first use in the abstract.
Presentation: A Presenting Author whose abstract has been accepted for either oral, or poster presentation is required to register and pay the conference registration fee in order to attend the meeting, and deliver their abstract.
Abstracts accepted as oral presentations will be given 15 minutes of presentation, including three minutes for question and answer session. Presenters will be requested to submit their PowerPoint presentations saved on a CD, DVD or memory sticks (using the USB port in the computer) and uploaded in the Speakers’ Ready Room at least two hours before the start of your session. If you have a video embedded on your PowerPoint presentation, please check that the video file works properly in the hall where your presentation is taking place during a break immediately prior to your session even after you checked in in the Speakers’ Ready Room.
The meeting rooms will be equipped with PC – based laptops.
Macintosh users should make sure that they have converted their presentation files to formats that are compatible with PC computers. Please read the instructions furnished below before submitting your presentation to the meeting organizers:
Use these fonts as other fonts may change to a default font on a PowerPoint-based PC: Arial; Times New Roman, Verdana.
Insert photos that are JPG files. Please note that images saved as TIF, PNG or PICT will not be visible on a PowerPoint-based PC.
Use AVI, MPG and WMV files as MOV files from QuickTime will not be visible on a PowerPoint-based PC.
Display boards for poster exhibition will be provided on-site. Poster panel’s usable size: 2223mm (Height) X 970mm (Width). Please prepare your A0 size poster in PORTRAIT layout. You are required to develop, print, and bring along the poster to the venue for mounting onto the poster board. For legibility, a minimum font size of 28 points and a maximum of 600 words on each poster are recommended. Double-sided tape will be provided to mount your poster.
For Sponsorship and Exhibition inquiries, please contact:
Tel: +971 4 311 6300
Bayer is an innovation company with a more than 150-year history and core competencies in the fields of health care and agriculture. We develop new molecules for use in innovative products and solutions to improve the health of humans, animals and plants. Our research and development activities are based on a profound understanding of the biochemical processes in living organisms.
An analysis by well-known branding agency Interbrand in 2015 valued the Bayer brand at €6.3 billion.
Our goal is to achieve and sustain leadership positions in our markets, thus creating value for our customers, stockholders and employees. To this end, our strategy is designed to help solve some of the most pressing challenges facing mankind, and by doing this exceptionally well we aim to strengthen the company’s earning power.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its manufacturing expertise to strive for solutions dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
MSD also known as Merck Sharp & Dohme Corp., (a subsidiary of Merck & Co., Inc.,Whitehouse Station, NJ, USA) is a global research-driven pharmaceutical companydedicated to putting patients first. Established in 1891, MSD discovers, develops,manufactures and markets vaccines and medicines to address unmet medical needs.MSD has been present for over than 30 years in the GULF region. MSD GULF operatesthroughout offices based in the UAE, Kuwait, Bahrain, Qatar & Oman and ranksamongst the leading pharmaceutical companies throughout the GULF region. Throughits local distributors, MSD GULF provides innovative medications in several diseaseentities. These include products for Anti- Infectives, Cardiovascular, Asthma & Allergy,Diabetes, HCV, HIV, Pain & Inflammation, Osteoporosis, Oncology, Fertility,Ophthalmic, and Anesthesia in addition to several specialized Vaccines.
Julphar is the largest generic pharmaceutical manufacturer in MENA. For over thirty years, we have been providing high quality, affordable medicines to families across the region. We operate thirteen internationally accredited facilities in the UAE and others located in Ethiopia, Bangladesh and KSA. We maintain a large and diverse range of medicines targeting major therapeutic segments, inclusive of biotechnology. Our strong network ensures distribution to over 40 countries worldwide.
Marketing Executive , MCI Dubai